B
Bull
Bull · 25%CRDL
$1.28
Szenariopreis
$1.975
+0.036 (+1.80%)Zum Schluss
Loading chart…
- High
- 1.980
- Open
- 1.920
- VWAP
- 1.95
- Vol
- 780.88K
- Mkt Cap
- 138.00M
- Low
- 1.880
- Amount
- 1.52M
- EV/EBITDA, TTM
- 0.00
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
AI analysis of Cardiol Therapeutics Inc (CRDL)
buyCardiol Therapeutics Inc is a good buy right now due to its current price of $1.94, which is significantly lower than the analyst price target of $11, indicating a potential upside of over 465%. Additionally, the company has shown a year-to-date change of +95.13%, reflecting strong momentum. The main risk is the negative earnings per share of -0.05 reported for Q2 2026, which indicates ongoing losses but is improving compared to previous quarters.
Bewertungskennzahlen
The current forward P/E ratio for Cardiol Therapeutics Inc (CRDL) is 0.00, compared to its 5-year average forward P/E of -3.79.
Alphio AI Price Scenarios for CRDL
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
1.008-05PRnewswireCardiol Therapeutics to Participate in Growth Conference
9.007-14PRnewswireJAHA Publishes Phase II MAVERIC Data, Strengthening CardiolRx Basis as Phase III Enrollment Nears Completion
4.507-14NewsfilterJAHA Publication Strengthens MAVERIC Phase III Prospects as Enrollment Nears Completion
8.507-09PRnewswireCardiol Therapeutics to Participate in B. Riley Summit
- 8.507-09Newsfilter
Cardiol Therapeutics to Participate in B. Riley Summit
CRDL FAQ — answered by Alphio AI
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
Cardiol Therapeutics Inc is a good buy right now due to its current price of $1.94, which is significantly lower than the analyst price target of $11, indicating a potential upside of over 465%. Additionally, the company has shown a year-to-date change of +95.13%, reflecting strong momentum. The main risk is the negative earnings per share of -0.05 reported for Q2 2026, which indicates ongoing losses but is improving compared to previous quarters.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.